Literature DB >> 16502127

New discoveries in the pathogenesis of renal osteodystrophy.

Richard J Lund1, Matthew R Davies, Suresh Mathew, Keith A Hruska.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16502127     DOI： 10.1007/s00774-005-0666-8

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN： 0914-8779            Impact factor:   2.626


× No keyword cloud information.
  10 in total

1.  Older women with diabetes have an increased risk of fracture: a prospective study.

Authors:  A V Schwartz; D E Sellmeyer; K E Ensrud; J A Cauley; H K Tabor; P J Schreiner; S A Jamal; D M Black; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

2.  Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7.

Authors:  Esther A González; Richard J Lund; Kevin J Martin; John E McCartney; M Mehrdad Tondravi; T Kuber Sampath; Keith A Hruska
Journal:  Kidney Int       Date:  2002-04       Impact factor: 10.612

Review 3.  Regulation of vascular calcification: roles of phosphate and osteopontin.

Authors:  Cecilia M Giachelli; Mei Y Speer; Xianwu Li; Rupak M Rajachar; Hsueh Yang
Journal:  Circ Res       Date:  2005-04-15       Impact factor: 17.367

Review 4.  Hyperphosphatemia: pharmacologic intervention yesterday, today and tomorrow.

Authors:  H H Malluche; M C Monier-Faugère
Journal:  Clin Nephrol       Date:  2000-10       Impact factor: 0.975

5.  Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3.

Authors:  Reinhold G Erben; Lis Mosekilde; Jesper S Thomsen; Karin Weber; Kerstin Stahr; Alyson Leyshon; Susan Y Smith; Roger Phipps
Journal:  J Bone Miner Res       Date:  2002-08       Impact factor: 6.741

6.  Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome.

Authors:  Matthew R Davies; Richard J Lund; Suresh Mathew; Keith A Hruska
Journal:  J Am Soc Nephrol       Date:  2005-03-02       Impact factor: 10.121

7.  BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure.

Authors:  Matthew R Davies; Richard J Lund; Keith A Hruska
Journal:  J Am Soc Nephrol       Date:  2003-06       Impact factor: 10.121

8.  Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat.

Authors:  S Vukicevic; V Basic; D Rogic; N Basic; M S Shih; A Shepard; D Jin; B Dattatreyamurty; W Jones; H Dorai; S Ryan; D Griffiths; J Maliakal; M Jelic; M Pastorcic; A Stavljenic; T K Sampath
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

9.  Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model.

Authors:  Richard J Lund; Matthew R Davies; Alex J Brown; Keith A Hruska
Journal:  J Am Soc Nephrol       Date:  2004-02       Impact factor: 10.121

10.  Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.

Authors:  W G Goodman; J A Ramirez; T R Belin; Y Chon; B Gales; G V Segre; I B Salusky
Journal:  Kidney Int       Date:  1994-10       Impact factor: 10.612
  10 in total
  4 in total

Review 1.  Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update.

Authors:  Alessandro Di Cerbo; Federica Pezzuto; Lucia Palmieri; Valentina Rottigni; Tommaso Iannitti; Beniamino Palmieri
Journal:  Int Urol Nephrol       Date:  2013-04-13       Impact factor: 2.370

2.  Deletion of FoxO1, 3, and 4 in Osteoblast Progenitors Attenuates the Loss of Cancellous Bone Mass in a Mouse Model of Type 1 Diabetes.

Authors:  Srividhya Iyer; Li Han; Elena Ambrogini; Maria Yavropoulou; John Fowlkes; Stavros C Manolagas; Maria Almeida
Journal:  J Bone Miner Res       Date:  2016-09-07       Impact factor: 6.741

Review 3.  Sclerostin and CKD-MBD.

Authors:  Susan C Schiavi
Journal:  Curr Osteoporos Rep       Date:  2015-06       Impact factor: 5.096

4.  [Metabolic bone diseases].

Authors:  F Jakob
Journal:  Internist (Berl)       Date:  2007-10       Impact factor: 0.743
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.